Specialty Dispensing Insights delivers practice, clinic, and physician level perspective on oral therapy use within medically integrated dispensing (MID) pharmacies, including dose and days’ supply metrics, ZIP based activity, competitive prescribing, and trends in new patient starts. These insights offer clear visibility into how oral therapies are utilized within MID practices, helping teams understand the unique prescribing dynamics, geographic variation, and competitive activity across real-world community settings.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
